CTLA4 and melanoma: Blocking antibodies of programmed death-1 (PD1) and cytotoxic T-lymphocyte–associated protein (CTLA-4) introduced a dramatic change in metastatic melanoma patients' treatment and prognosis, intensifying the proportion of responding melanoma patients[3].